CoChat

Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance

Open access
Pearson, Alex, Proszek, Paula, Pascual, Javier, Fribbens, Charlotte, Shamsher, Monee K., Kingston, Belinda, O'Leary, Ben, Herrera-Abreu, Maria T., Cutts, Rosalind J., Garcia-Murillas, Isaac, Bye, Hannah, Walker, Brian A., Gonzalez De Castro, David, Yuan, Lina, Jamal, Sabri, Hubank, Mike, Lopez-Knowles, Elena, Schuster, Eugene F., Dowsett, Mitch, Osin, Peter, Nerurkar, Ashutosh, Parton, Marina, Okines, Alicia F.C., Johnston, Stephen R.D., Ring, Alistair, Turner, Nicholas C. · 2020 · Clinical Cancer Research
Cited by 136

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Purpose: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential to acquire mutations with resistance to treatment and disease progression. To identify potentially targetable mutations in advanced breast cancer, we performed prospective molecular characterization of a cohort of patients with ABC. Experimental Design: Biopsies from patients with advanced breast cancer were sequenced with a 41 genes targeted panel in the ABC Biopsy (ABC-Bio) study. Blood samples were collected at disease progression for circulating tumor DNA (ctDNA) analysis, along with matched primary tumor to assess for acquisition in ABC in a subset of patients. Results: We sequenced 210 ABC samples, demonstrating enrichment compared with primary disease for potentially targetable mutations in HER2 (in 6.19% of samples), AKT1 (7.14%), and NF1 (8.10%). Of these enriched mutations, we show that NF1 mutations were frequently acquired in ABC, not present in the original primary disease. In ER-positive cancer cell line models, loss of NF1 resulted in endocrine therapy resistance, through both ER-dependent and -independent mechanisms. NF1 loss promoted ER-independent cyclin D1 expression, which could be therapeutically targeted with CDK4/6 inhibitors in vitro. Patients with NF1 mutations detected in baseline circulating tumor DNA had a good outcome on the CDK4/6 inhibitor palbociclib and fulvestrant. Conclusions: Our research identifies multiple therapeutic opportunities for advanced breast cancer and identifies the previously underappreciated acquisition of NF1 mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-4044

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 136

Metadata

Authors
Pearson, A., Proszek, P., Pascual, J., Fribbens, C., Shamsher, M. K., Kingston, B., O'Leary, B., Herrera-Abreu, M. T., Cutts, R. J., Garcia-Murillas, I., Bye, H., Walker, B. A., Gonzalez De Castro, D., Yuan, L., Jamal, S., Hubank, M., Lopez-Knowles, E., Schuster, E. F., Dowsett, M., Osin, P., Nerurkar, A., Parton, M., Okines, A. F. C., Johnston, S. R. D., Ring, A., & Turner, N. C.
Venue
Clinical Cancer Research
Published
2020-02-01
Volume
26
Issue
3
Pages
608-622
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2979439917
Cited by
136
References
10
FWCI
8.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-4044
The paper
Pearson, A., Proszek, P., Pascual, J., Fribbens, C., Shamsher, M. K., Kingston, B., O'Leary, B., Herrera-Abreu, M. T., Cutts, R. J., Garcia-Murillas, I., Bye, H., Walker, B. A., Gonzalez De Castro, D., Yuan, L., Jamal, S., Hubank, M., Lopez-Knowles, E., Schuster, E. F., Dowsett, M., . . . Turner, N. C. (2020). Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-4044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.